Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11371451 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP2C19USP2TSHR | |
| SCHEMBL11253304 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP2C19USP2TSHR | |
| SCHEMBL11245376 | 0.97 | — | — | |
| SCHEMBL27386312 | 0.78 | — | — | |
| SCHEMBL26556808 | 0.78 | — | — | |
| SCHEMBL11247629 | 0.75 | JAK2 (0.30) | — | |
| SCHEMBL11238388 | 0.75 | — | — | |
| SCHEMBL11250288 | 0.75 | — | — | |
| SCHEMBL9014795 | 0.74 | ALDH1A1 (0.35) | ALDH1A1CYP2C19USP2TSHR | |
| SCHEMBL27651887 | 0.74 | CYP2C19 (0.35) | ALDH1A1CYP2C19USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4496762-A | Process for the preparation of N-(2-(cyclo-hexen-1-yl)ethyl)-4-methoxybenzeneacetamide | EASTMAN KODAK COMPANY (US) | 1985-01-29 | — | — | US | claimed |
| EP-4015513-B1 | IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEV CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4015513-A1 | IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021057785-A1 | IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| WO-1996022969-A1 | PROCESS FOR THE PRODUCTION OF (1-HYDROXYCYCLOHEXANE)-ACETRONITRILE | LONZA AG (CH) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996022969-A1 | PROCESS FOR THE PRODUCTION OF (1-HYDROXYCYCLOHEXANE)-ACETRONITRILE | LONZA AG (CH) | 1996-08-01 | — | — | WO | disclosed |
| EP-0505089-B1 | A catalyst for asymmetric induction | SUMITOMO CHEMICAL CO (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-5288682-A | Catalyst for asymmetric induction | SUMITOMO CHEMICAL CO., LTD. (JP) | 1994-02-22 | — | — | US | disclosed |
| US-4496762-A | Process for the preparation of N-(2-(cyclo-hexen-1-yl)ethyl)-4-methoxybenzeneacetamide | EASTMAN KODAK COMPANY (US) | 1985-01-29 | — | — | US | disclosed |
| US-4341789-A | ANTISECRETORY, ANTIAGGLOMERANTS, BRONCHODILATOR AND ANTIFERTILITY AGENTS | BEECHAM GROUP LIMITED (GB) | 1982-07-27 | — | — | US | disclosed |
| EP-0001900-B1 | 9-THIA-12-AZAPROSTANOIC ACID DERIVATIVES AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1982-04-07 | — | — | EP | disclosed |
| US-4260771-A | VASODILATORS, ANTICOAGULANTS, IMMUNOLOGY | MERCK & CO., INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4225609-A | Interphenylene 9-thia-11-oxo-12-aza-prostanoic acids | MERCK & CO., INC. (US) | 1980-09-30 | — | — | US | disclosed |
| US-4201864-A | CHEMICAL INTERMEDIATES, PROSTAGLANDINS | BEECHAM GROUP LIMITED (GB) | 1980-05-06 | — | — | US | disclosed |
| US-4177283-A | ANTISECRETORY, ANTICOAGULANT, BRONCHODILATOR | BEECHAM GROUP LIMITED (GB) | 1979-12-04 | — | — | US | disclosed |
| EP-0001900-A1 | 9-Thia-12-azaprostanoic acid derivatives and compositions containing them | MERCK & CO. INC. (US) | 1979-05-16 | — | — | EP | disclosed |
| US-4138407-A | ANTISECRETORY, BRONCHODILATOR, ANTICOAGULANT | BEECHAM GROUP LIMITED (GB) | 1979-02-06 | — | — | US | disclosed |
| US-4022794-A | VASODILATION | MERCK & CO., INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | ALDH1A1 111/4885CYP2C19 33/4885USP2 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.